A Novel Liposomal Bupivacaine Formulation to Produce Ultralong-Acting Analgesia
Authors:
- Gilbert J. GrantGGGilbert J. Grant
- Yechezkel BarenholzYBYechezkel Barenholz
- Elijah M. BolotinEBElijah M. Bolotin
- Mylarrao BansinathMBMylarrao Bansinath
- Herman TurndorfHTHerman Turndorf
- Boris PiskounBPBoris Piskoun
- Elyad M. DavidsonEDElyad M. Davidson
- 1 July 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 101 (1) , 133-137
Abstract
Background: Currently available local anesthetics have relatively brief durations of action. An ultralong-acting local anesthetic would benefit patients with acute and chronic pain. The authors prepared and characterized a novel liposomal bupivacaine formulation using remote loading of bupivacaine along an ammonium sulfate gradient and assessed its efficacy in humans. Methods: A large multivesicular liposomal bupivacaine formulation was prepared by subjecting small unilamellar vesicles to successive freeze-and-thaw cycles. Bupivacaine hydrochloride was then remotely loaded into the liposomes along an ammonium sulfate gradient ([(NH4)2SO4)]intraliposome/[(NH4)2SO4)]medium > 1000). The liposomes were then characterized for size distribution; drug-to-phospholipid ratio; in vitro release profile at 4 degree, 21 degree C, and 37 degree C; sterility; and pyrogenicity. Six subjects each received six intradermal injections in the lower back with 0.5 ml of 0.5, 1.0, and 2% liposomal bupivacaine; 0.5% standard bupivacaine; saline; and "empty" liposomes. Duration of analgesia was assessed using pinprick testing of the skin directly over the injection sites. Results were compared using the log-rank test. Results: The mean large multivesicular vesicle size was 2439 +/- 544 nm, with a drug-to-phospholipid ratio of 1.8, fivefold greater than results previously reported. In vitro release was slowest at 4 degree C. The median duration of analgesia with 0.5% standard bupivacaine was 1 h. The median durations of analgesia after 0.5, 1.0, and 2.0% liposomal bupivacaine were 19, 38, and 48 h, respectively. Neither saline nor "empty" liposomes produced analgesia. Conclusions: This novel liposomal formulation had a favorable drug-to-phospholipid ratio and prolonged the duration of bupivacaine analgesia in a dose-dependent manner. If these results in healthy volunteers can be duplicated in the clinical setting, this formulation has the potential to significantly impact the management of pain.Keywords
This publication has 19 references indexed in Scilit:
- The Holy Grail: long-acting local anaesthetics and liposomesBest Practice & Research Clinical Anaesthesiology, 2002
- DRV Liposomal Bupivacaine: Preparation, Characterization, and In Vivo Evaluation in MicePharmaceutical Research, 2001
- Liposomal Delivery Systems for Local AnestheticsRegional Anesthesia & Pain Medicine, 2001
- Acute painThe Lancet, 1999
- Wound infiltration with liposomal bupivacaine prolongs analgesia in ratsActa Anaesthesiologica Scandinavica, 1997
- Liposomal BupivacaineAnesthesiology, 1996
- Epidural administration of liposome associated bupivacaine for the management of postsurgical pain: A first studyJournal of Clinical Anesthesia, 1994
- Noninvasive Percutaneous Induction of Topical Analgesia by a New Type of Drug Carrier, and Prolongation of Local Pain Insensitivity by Anesthetic LiposomesAnesthesia & Analgesia, 1992
- Prolongation of Canine Epidural Anesthesia by Liposome Encapsulation of LidocaineAnesthesia & Analgesia, 1992
- Topical Anesthesia of the Skin by Liposome-Encapsulated TetracaineAnesthesia & Analgesia, 1988